BRAF and melanoma: The phase III randomized trial, DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) [4], compared the efficacy and toxicity of nivolumab/ipilimumab followed by dabrafenib/trametinib to the converse sequence progression in 265 patients with advanced BRAF V600-mutant melanoma.